For the quarter ending 2025-09-30, CRNX made $143,000 in revenue. -$129,518,000 in net income. Net profit margin of -90572.03%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Revenues | 143,000 | 1,031,000 | 361,000 | 259,750 |
| Research and development | 90,464,000 | 80,301,000 | 76,240,000 | 59,417,000 |
| Selling, general and administrative | 52,265,000 | 49,842,000 | 35,526,000 | 24,615,000 |
| Total operating expenses | 142,729,000 | 130,143,000 | 111,766,000 | 84,032,000 |
| Loss from operations | -142,586,000 | -129,112,000 | -111,405,000 | -83,685,666.667 |
| Other income (expense), net | - | 20,000 | -203,000 | -160,666.667 |
| Interest income | 12,544,000 | 13,455,000 | 14,834,000 | 10,143,000 |
| Other expense, net | -49,000 | - | - | - |
| Total other income, net | 12,495,000 | 13,475,000 | 14,631,000 | 9,982,333.333 |
| Loss before equity method investment | -130,091,000 | 115,637,000 | 96,774,000 | 73,703,333.333 |
| Loss on equity method investment | 0 | - | - | -117,500 |
| Net loss | -130,091,000 | -115,637,000 | -96,774,000 | -73,860,000 |
| Unrealized gain on investment securities | 594,000 | -347,000 | 1,033,000 | -747,333.333 |
| Unrealized loss on foreign currency | -21,000 | -34,000 | 6,000 | - |
| Total other comprehensive income | 573,000 | -381,000 | 1,039,000 | - |
| Comprehensive loss | -129,518,000 | -116,018,000 | -95,735,000 | -74,607,333.333 |
| Net loss per share - basic (in dollar per share) | -1.38 | -1.23 | -1.04 | -0.91 |
| Net loss per share - diluted (in dollar per share) | -1.38 | -1.23 | -1.04 | -0.91 |
| Weighted average shares - basic (in shares) | 94,215,000 | 93,791,000 | 93,102,000 | 230,666.667 |
| Weighted average shares - diluted (in shares) | 94,215,000 | 93,791,000 | 93,102,000 | 230,666.667 |
Crinetics Pharmaceuticals, Inc. (CRNX)
Crinetics Pharmaceuticals, Inc. (CRNX)